Eli Lilly
3,900 hedge funds and large institutions have $583B invested in Eli Lilly in 2025 Q3 according to their latest regulatory filings, with 214 funds opening new positions, 1,795 increasing their positions, 1,458 reducing their positions, and 164 closing their positions.
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
8% less call options, than puts
Call options by funds: $12.7B | Put options by funds: $13.9B
1.82% less ownership
Funds ownership: 82.67% → 80.85% (-1.8%)
13% less funds holding in top 10
Funds holding in top 10: 291 → 254 (-37)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 | +$3.22B | |
| 2 | +$1.26B | |
| 3 | +$858M | |
| 4 |
Amundi
Paris,
France
|
+$718M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$554M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 | -$2.51B | |
| 2 | -$1.98B | |
| 3 | -$1.67B | |
| 4 |
Tiger Global Management
New York
|
-$1.18B |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.08B |
LLY Hedge Fund Activity: Q3 2025 in Review
3,900 of the 7,631 institutional investors tracked by Wall St. Rank reported a position in Eli Lilly (LLY) for Q3 2025, worth a combined $583B — down 4.4% from $610B a quarter earlier.
Buyers outnumbered sellers: 214 funds opened new LLY positions and 164 closed out — a net gain of 50 holders — while 1,795 added to existing stakes and 1,458 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $3.22B. The largest seller was T. Rowe Price Associates, cutting an estimated $2.51B.
- 3,900 institutional investors held Eli Lilly (LLY) as of Q3 2025, down from 3,913 in Q2 2025.
- Funds reported $583B of Eli Lilly stock for Q3 2025, down 4.4% quarter-over-quarter.
- 214 funds opened new Eli Lilly positions in Q3 2025 and 164 closed out, a net change of +50 holders.
- The largest Eli Lilly buyer in Q3 2025 was Capital Research Global Investors, an estimated $3.22B added.
- The largest Eli Lilly seller in Q3 2025 was T. Rowe Price Associates, an estimated $2.51B sold.
Based on aggregated 13F filings for Q3 2025.